The titration schedule printed on the package is a protocol designed for clinical trials, where every participant moves up on the same timeline regardless of how they're doing. Clinical practice is different. Knowing when to hold, when to push, and when the dose is actively wrong — too high or too low — produces a meaningfully better experience than following a fixed calendar.
How Titration Works and Why
For semaglutide (Wegovy), the standard titration runs: 0.25 mg weekly for four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching 2.4 mg as the maintenance target. For tirzepatide (Zepbound), the ladder is: 2.5 mg for four weeks, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg — each step spaced four weeks apart, with a total ramp of about five months to the maximum dose.
These schedules exist primarily to allow the gastrointestinal tract to adapt, not to optimize the speed of weight loss. GLP-1 receptor agonists slow gastric emptying, reduce GI motility, and alter gut peptide secretion. Introducing a therapeutically active dose abruptly produces nausea, vomiting, and constipation in a majority of patients. The titration period is GI conditioning, not dose optimization.
The phase 3 trials (STEP for semaglutide, SURMOUNT for tirzepatide) used rigid titration schedules because research protocols require standardization. They were not asking "what is the optimal individual titration strategy?" They were asking "what does this drug do at these doses when cranked up on a fixed schedule?" The answer was robust weight loss data. The interpretation that everyone must follow that exact ramp in clinical practice is an overextension of what the trials showed.
Faster escalation does not produce better long-term outcomes. It produces more side effects in the short term without meaningful improvement in weight loss at one year. This is not theoretical — the trial data consistently shows that the total weight loss achieved is governed by the maintenance dose reached, not by how quickly you got there.
When to Hold Your Dose
The clearest indication to hold a dose rather than escalate: you are still experiencing meaningful nausea, vomiting, or other GI symptoms at your current dose level. Escalating into active side effects is the fastest route to discontinuing the medication, either because the patient stops voluntarily or because the prescriber has to step back anyway.
A practical framework used in clinical practice rates side effects on a simple 0–5 scale. At 0–2 (minimal to mild, not affecting daily function), escalation is appropriate when other conditions are met. At 3–5 (moderate to severe, affecting daily activities, requiring behavioral accommodation), staying at the current dose is the correct move until the side effect burden drops.
"Staying at a dose" does not mean failure. Some patients find that they are comfortable, appetite is well-controlled, and weight is moving at a steady pace at 5 mg tirzepatide or 0.5 mg semaglutide — well below the maximum. Those are patients who either respond with high sensitivity at lower doses or have reached their effective therapeutic window without needing the ceiling. Both are legitimate. The goal is the clinical outcome (meaningful weight loss, metabolic improvement), not reaching a specific dose.
Weight loss pace is the other holding signal. Losing more than 1% of total body weight per week is a reason to hold rather than escalate. Faster loss increases the risk of gallstone formation — GLP-1 therapy already slightly elevates gallbladder risk, and rapid weight loss amplifies it significantly. Faster loss also increases the proportion of weight lost from lean mass rather than fat, which is counterproductive for long-term metabolic health and body composition. At 200 lbs, 1% per week is 2 lbs; that is a reasonable ceiling pace.
Note(The gallstone risk at rapid weight loss)
GLP-1 drugs slow gallbladder contractility, and rapid weight loss independently raises biliary cholesterol saturation. The combination means patients losing weight quickly are at elevated risk for gallstones. Staying at 0.5–1% total body weight loss per week reduces this risk. If you have right upper quadrant discomfort on these medications, flag it — do not assume it's GI side effects from the drug.
Signs Your Dose Is Wrong — Too High
The signals that a dose is above what you need:
Persistent nausea beyond two to four weeks at a stable dose. Some nausea at the time of escalation is expected and typically resolves within two weeks as the GI tract adapts. Nausea that remains significant at a dose you've been on for a month is telling you the dose is above your tolerance threshold, not that you need to wait longer.
Significant fatigue. Some patients experience tiredness on GLP-1 therapy that is disproportionate to their caloric deficit. Clinically, this often improves on dose reduction. The mechanism likely involves GLP-1 receptor activity in brainstem circuits that regulate arousal and energy expenditure — the same circuits that can cause early insomnia (see the sleep post in this series).
Appetite suppression so severe you are undereating. If you are eating 600–800 kcal daily not because you're making an effort to restrict but because you have no appetite and food is aversive, the dose is likely too high for safe long-term use. Severe underfeeding accelerates muscle loss, worsens metabolic adaptation, elevates cortisol, and is not necessary — the trials showing 15–20% weight loss were conducted at moderate caloric deficits, not near-starvation.
Motivational flatness or sleep disruption that persists at a stable dose. These are neurological signals, not GI ones, and they point to the drug's dose-dependent effects on mesolimbic and brainstem circuits being above what is needed for the therapeutic effect.
The solution to being over-dosed is nearly always stepping back one level, not discontinuing. Most patients who drop from 15 mg to 10 mg tirzepatide, or from 2.4 mg to 1.7 mg semaglutide, experience resolution of side effects without meaningful weight regain, because the difference in efficacy between adjacent doses is modest compared to the difference in side effect burden at the extremes.
Signs Your Dose Is Wrong — Too Low
The signals that you need to escalate:
No change in appetite or food noise after four to six weeks at a stable dose. A therapeutically active dose of a GLP-1 drug produces a subjective change in food preoccupation, appetite, and eating behavior within a few weeks. If you are at a stable dose for six weeks and feel no different from before starting — same hunger, same food thoughts, same eating pattern — the dose is not yet producing a therapeutic effect. This is when escalation is indicated.
No weight change over four to six weeks at a stable dose. Some weight stalls are dietary — caloric intake crept back up, activity decreased. But a flat weight at a dose that is producing no appetite change, where the patient reports eating the same amount as before starting, is a dose signal.
The important distinction: not losing as fast as you'd like is not a sign your dose is too low. If the drug is suppressing appetite, food noise is quiet, you're eating less, and weight is moving at 0.5–1% per week — that is the drug working. The appropriate response is not escalation; it's patience. Escalation to accelerate an already-productive rate of loss is how you end up at a dose that's above your therapeutic window.
Warning(Impatience is not a dosing signal)
The standard titration schedule takes five months to reach maximum tirzepatide dose. Patients who feel the drug isn't working fast enough and push to escalate — despite active appetite suppression and steady weight loss — are increasing their risk of side effects without improving their eventual outcome. The rate of weight loss, not the number of pounds lost, is what matters when assessing whether a dose is working.
Microdosing
Microdosing refers to using sub-starting doses of GLP-1 drugs, typically from compounded versions — doses well below the 0.25 mg starting dose for semaglutide or the 2.5 mg starting dose for tirzepatide. The term was popularized largely in online health communities, but the clinical concept is older.
The evidence for true microdosing as a weight-loss strategy is weak. Phase 2 dose-ranging data for semaglutide from 2016 showed that the 0.1 mg dose (true microdose territory) produced weight loss comparable to or slightly below placebo — the active drug at very low doses was essentially indistinguishable from doing nothing for weight and glycemia. Meaningful efficacy in the dose-ranging trials began at approximately 0.2–0.4 mg weekly.
Where low-dose approaches have genuine clinical rationale:
Sensitivity to side effects. Some patients cannot tolerate even the standard 0.25 mg starting dose of semaglutide and experience significant nausea. Going below the starting dose — 0.1–0.12 mg using an Ozempic pen with dose splitting — can allow GI adaptation before reaching therapeutic doses. This is a stepping-stone, not a destination.
Maintenance at lower than maximum doses. A patient who has reached their weight goal, has stable metabolic parameters, and does not want to escalate to the maximum dose can sometimes maintain their outcome at 0.5 mg semaglutide (the type 2 diabetes maintenance dose) or 5–7.5 mg tirzepatide. Some GLP-1R activity is better than none when the alternative is stopping entirely and risking regain.
The important caveat on compounded versions: the cardiovascular outcome data, the OSA trial data, the SELECT trial — all of it was generated on studied, pharmaceutical-grade, validated doses of the approved drug. If you are using a compounded version at a non-standard dose, you do not have that evidence applying to you. The pharmacology is likely similar; the long-term risk and benefit data is not transferable.
Maintenance Dosing vs. Weight Loss Dosing
The dose required to reach a weight goal is not necessarily the dose required to maintain it. This distinction is clinically important and underutilized.
The phase 4 extension data (SURMOUNT-4 for tirzepatide, STEP-4 for semaglutide) shows that patients who transition to a lower maintenance dose after reaching their goal tend to do substantially better than those who stop the drug entirely. Weight regain on complete discontinuation is the dominant pattern — the hormonal drivers of weight regain reassert themselves rapidly when GLP-1R agonism is removed. A lower maintenance dose blunts this regain without maintaining the full cost and side effect profile of the weight-loss dose.
In clinical practice, many patients who were losing weight at 10 or 12.5 mg tirzepatide can maintain their achieved weight at 5–7.5 mg. The strategy worth trying before stopping entirely: step down one or two dose levels, monitor for regain over six to eight weeks, and assess whether the lower dose is sufficient to hold the metabolic gains. Many patients find it is.
Switching Drugs
Switching between GLP-1 agents — or from a GLP-1 to a GIP/GLP-1 dual agonist — is increasingly common as the landscape expands and as patient experience accumulates.
When switching makes sense: Intractable nausea on semaglutide that has not resolved across multiple dose levels and an adequate adaptation period. Plateau at maximum semaglutide dose, with room to benefit from the additional GIP agonism of tirzepatide. Significant cost differences based on insurance coverage.
How to switch: No washout period is required when moving between agents in this class. The practical approach is to stop the current drug and start the new one at its lowest dose on the next injection day, then titrate normally. Starting the new drug at a higher dose — even if you were at a high dose on the previous agent — carries a meaningful risk of GI side effects because GI adaptation is somewhat drug-specific.
Pipeline options — including retatrutide (the triple GLP-1/GIP/glucagon agonist), oral semaglutide at higher doses, and longer-acting formulations — are in late-stage development. The glucagon agonism in retatrutide appears to directly increase resting metabolic rate in a way that the current GIP/GLP-1 agents may not, which is why early data shows substantially greater weight loss. That mechanism comes with a more aggressive side effect and monitoring profile, and it is likely to be reserved initially for patients with severe obesity and significant comorbidities.
User Sentiment
The most common dosing-related themes in patient communities center on two frustrations: patients who were pushed up the schedule too fast and had severe side effects that caused them to quit, and patients who stayed too long at an ineffective low dose and concluded the drug didn't work for them. Both scenarios are avoidable with attention to the signals the dose is sending.
Example(What the community says)
"My doctor wanted me at 5mg by month two. I was still nauseous at 2.5mg. I pushed back, stayed there longer, and eventually got to 10mg with almost no side effects."
"I was on 0.25mg for three months and lost maybe 3 lbs. My doctor didn't tell me that's basically a starter dose, not a therapeutic dose."
"I dropped from 15mg to 10mg because I felt blah and didn't want to work out. Lost more weight at 10mg because I started moving again."
Who It's For
Anyone on GLP-1 therapy navigating a decision about whether to escalate, hold, reduce, or switch their dose. Also useful for patients who were told they "failed" at a given dose without understanding whether the problem was tolerance, inadequate time at a therapeutic dose, or being above their effective range.
Summary(The short version)
The titration schedule conditions the GI tract — it is not the optimal dosing protocol for every individual. Hold escalation when GI side effects are still significant; staying at a dose is not failure. Signs you're too high: persistent nausea past two to four weeks at a stable dose, severe fatigue, food aversion, motivational flatness — step back one level. Signs you're too low: no change in appetite or weight after four to six weeks — escalate. True microdosing (below 0.25 mg semaglutide) produces minimal metabolic effect; low-dose maintenance is different and can be effective. Many patients can maintain weight loss at a lower dose than they used to lose it — try stepping down before stopping entirely. Switching requires no washout; always start the new drug at its lowest dose.